Skip to content

Regeneron Inc., moves full steam ahead on European approval of Eylea (aflibercept)

Regeneron Inc., moves full steam ahead on European approval of Eylea (aflibercept)
Regeneron Inc., (Tarrytown, New York; NASDAQ:REGN) moved up $0.47 to $176.55 per share following the European Medicines Agency’s (EMA) approval of a Marketing Authorisation Application (MAA) from Bayer AG (Xetra: BAYN) for Eylea (aflibercept), indicated for the treatment of wet age-related macular degeneration (AMD). Bayer and Regeneron have partnering deals in place for the commercial development of the drug in which Regeneron maintains exclusive rights in the United States and Bayer has exclusive rights outside the United States, but will share profits made in other jurisdictions. Eylea has been approved in the U.S for both wet AMD and for macular edema following central retinal vein occlusion (CRVO). On November 27th, Regeneron announced that the European Medicines Agency (EMA) approved one 2 milligram (mg) injection per month for three consecutive months, followed by one injection every two months, with no requirement for monitoring by the physician between injections. After the first twelve months of treatment with the drug, the treatment interval may be extended based on visual and anatomic outcomes.